Fundraising Fox

Leap Therapeutics

Cambridge, US · Delaware corporation · 1 known investors

Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.

Biotech

Founders & leadership

JL
John LittlechildDirector
TD
Thomas DietzDirector
JL
Joseph LoscalzoDirector
NM
Nissim MashiachDirector
JC
James CavanaughDirector
DO
Douglas OnsiChief Financial Officer
CM
Christopher MirabelliChief Executive Officer, President and Director
WL
William LiDirector
AL
Augustine LawlorChief Operating Officer

Investors · 1

Torrey Pines InvestmentSan Diego

Reported raises · per SEC filings

Form D private placements
▶$77.2MraisedMar 2023 · 121 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph LoscalzoDirector
  • Christian RichardDirector
  • Christine GranfieldExecutive Officer
  • Patricia MartinDirector
  • Nissim MashiachDirector
  • Christopher K. MirabelliDirector
  • Cynthia SirardExecutive Officer
  • James CavanaughDirector
  • Richard SchilskyDirector
  • Augustine LawlorExecutive Officer
  • William LiDirector
  • Thomas DietzDirector
  • Mark O'MahonyExecutive Officer
  • Douglas E. OnsiExecutive Officer, Director
Offering amount
$77.2M
Amount sold
$77.2M
First sale
Jan 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18MraisedNov 2017 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John LittlechildDirector
  • Thomas DietzDirector
  • Joseph LoscalzoDirector
  • Nissim MashiachDirector
  • James CavanaughDirector
  • Douglas OnsiExecutive Officer
  • Christopher MirabelliExecutive Officer, Director
  • William LiDirector
  • Augustine LawlorExecutive Officer
Offering amount
$18M
Amount sold
$18M
Sales commissions
$400K
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.